Table 3. Patients Characteristics - Inter-rater reliability study.
| PSP | MSA | TOTAL | |
| N = 42 | N = 74 | N = 116 | |
| GENDER (F) | 46% | 45% | 46% |
| AGE (years) | 69±6 | 64±8 | 66±8 |
| AGE AT ONSET (years) (36–77) | 65±7 | 59±9 | 61±8 |
| DISEASE DURATION (years ) | 3.9±1.8 | 5.0±1.9 | 4.6±2.0 |
| 1–2 | 31% | 13% | 19% |
| 3–5 | 52% | 49% | 50% |
| 6–8 | 14% | 35% | 27% |
| >8 | 2% | 4% | 4% |
| CGI disease severity (1–6) | 3.5±1.0 | 3.7±.09 | 3.6±1.0 |
| Mild/Moderately ill | 48% | 45% | 46% |
| Markedly ill | 31% | 36% | 34% |
| Severely/Extremely ill | 21% | 19% | 20% |
| MODIFIED HOEHN & YAHR (0–5) Stage 2/2.5 | 24% | 13% | 17% |
| Stage 3 | 33% | 29% | 31% |
| Stage 4 | 12% | 35% | 26% |
| Stage 5 | 31% | 24% | 26% |
| SCHWAB & ENGLAND Activities of Daily living (0–100%) | 54±27 | 49±24 | 50±25 |
Clinical characteristics of the 116 patients who took part to the inter-rater reliability study. Patients were recruited from 11 centers within the 3 participating countries to the NNIPPS study. Characteristics of these patients were close to those of the overall population (n = 760) [8].
CGI = Clinical Global Impression; PSP = Progressive Supranuclear Palsy; MSA = Multiple System Atrophy.